Endocrinol Metab.  2024 Apr;39(2):310-323. 10.3803/EnM.2023.1870.

Cost-Utility Analysis of Early Detection with Ultrasonography of Differentiated Thyroid Cancer: A Retrospective Study on a Korean Population

• Baek HS
• Ha J
• Kim K
• Bae JS
• Kim JS
• Kim S
• Lim DJ
• Kim CM

• KMID: 2554636
• DOI: http://doi.org/10.3803/EnM.2023.1870

Abstract

Background
There is debate about ultrasonography screening for thyroid cancer and its cost-effectiveness. This study aimed to evaluate the cost-effectiveness of early screening (ES) versus symptomatic detection (SD) for differentiated thyroid cancer (DTC) in Korea.
Methods
A Markov decision analysis model was constructed to compare the cost-effectiveness of ES and SD. The model considered direct medical costs, health outcomes, and different diagnostic and treatment pathways. Input data were derived from literature and Korean population studies. Incremental cost-effectiveness ratio (ICER) was calculated. Willingness-to-pay (WTP) threshold was set at USD 100,000 or 20,000 per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted to address uncertainties of the model’s variables.
Results
In a base case scenario with 50 years of follow-up, ES was found to be cost-effective compared to SD, with an ICER of $2,852 per QALY. With WTP set at $100,000, in the case with follow-up less than 10 years, the SD was cost-effective. Sensitivity analysis showed that variables such as lobectomy probability, age, mortality, and utility scores significantly influenced the ICER. Despite variations in costs and other factors, all ICER values remained below the WTP threshold.
Conclusion
Findings of this study indicate that ES is a cost-effective strategy for DTC screening in the Korean medical system. Early detection and subsequent lobectomy contribute to the cost-effectiveness of ES, while SD at an advanced stage makes ES more cost-effective. Expected follow-up duration should be considered to determine an optimal strategy for DTC screening.

Keyword

Cost-effectiveness analysis; Papillary thyroid microcarcinoma; Quality of life; Watchful waiting; Endocrine surgical procedures

Figure

• 

  Fig. 1. The clinical scenario of ultrasonography examination for thyroid nodules. The health status in orange boxes are applied to Markov model. f/u, follow-up.

• 

  Fig. 2. Incremental cost-effectiveness ratio (ICER) and difference of net monetary benefit (NMB) according to termination stage of the constructed analysis model. Orange color: symptomatic detection (SD) is cost-effective; Blue color: early screening (ES) is cost-effective. (A) With willingness-to-pay (WTP) of $100,000, the difference of NMB changes to a positive number at stage 10, which means that the NMB of ES is higher than that of SD. (B) With WTP of $20,000, the difference of NMB changes to a positive number at stage 18, which means that the NMB of ES is higher than that of SD.

• 

  Fig. 3. (A) Incremental cost-effectiveness ratio (ICER) according to probability of lobectomy with early screening (ES). (B) ICER according to probability of lobectomy with symptomatic detection (SD). (C) ICER according to utility score after lobectomy. (D) ICER according to utility score after total thyroidectomy. QALY, quality-adjusted life year.

• 

  Fig. 4. Changes in incremental cost-effectiveness ratio (ICER) according to age and mortality. (A) ICER according to age. (B) ICER according to mortality after total thyroidectomy (TT). (C) ICER according to mortality with early screening (ES). (D) Net monetary benefit (NMB) according to mortality with symptomatic detection (SD). At base analysis, (mortality with SD, 0.0086), the NMB of ES is larger than those of SD. At point of 0.0049, the NMB of two strategies are cross over. QALY, quality-adjusted life year.

• 

  Fig. 5. Sensitivity analysis results while changing cost of surgery and ultrasonography. (A) Incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) changes according to cost of surgery. (B) ICER according to cost of ultrasonography (cost in tertiary hospital or in primary care clinic). (C) ICER according to ultrasonography interval with or without national insurance. Regular follow-up: once every 6 months for the first year, annual follow-up from 2 to 5 years, every 2 years for 5 to 10 years, every 3 years for 10 to 20 years, and every 5 years after 20 years. QALY, quality-adjusted life year; ES, early screening; SD, symptomatic detection.

Reference

1. Jung CK, Bae JS, Park YJ. Re-increasing trends in thyroid cancer incidence after a short period of decrease in Korea: reigniting the debate on ultrasound screening. Endocrinol Metab (Seoul). 2022; 37:816–8.

2. Choi YM, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, et al. Recent changes in the incidence of thyroid cancer in Korea between 2005 and 2018: analysis of Korean National Data. Endocrinol Metab (Seoul). 2022; 37:791–9.

3. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140:317–22.

4. Lee JY, Baek JH, Ha EJ, Sung JY, Shin JH, Kim JH, et al. 2020 Imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean Society of Thyroid Radiology. Korean J Radiol. 2021; 22:840–60.

5. Baek JH. Thyroid cancer screening: how to maximize its benefits and minimize its harms. Endocrinol Metab (Seoul). 2023; 38:75–7.

6. Moon S, Song YS, Jung KY, Lee EK, Park YJ. Lower thyroid cancer mortality in patients detected by screening: a meta-analysis. Endocrinol Metab (Seoul). 2023; 38:93–103.

7. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med. 2014; 371:1765–7.

8. Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ. 2016; 355:i5745.

9. Moon S, Lee EK, Choi H, Park SK, Park YJ. Survival comparison of incidentally found versus clinically detected thyroid cancers: an analysis of a nationwide cohort study. Endocrinol Metab (Seoul). 2023; 38:81–92.

10. Park YJ, Lee EK, Song YS, Kang SH, Koo BS, Kim SW, et al. 2023 Korean Thyroid Association management guidelines for patients with thyroid nodules. Int J Thyroidol. 2023; 16:1–31.

11. Yi KH, Kim SY, Kim DH, Kim SW, Na DG, Lee YJ, et al. The Korean guideline for thyroid cancer screening. J Korean Med Assoc. 2015; 58:302–12.

12. Yang N, Yang H, Guo JJ, Hu M, Li S. Cost-effectiveness analysis of ultrasound screening for thyroid cancer in asymptomatic adults. Front Public Health. 2021; 9:729684.

13. Baek HS, Jeong CH, Ha J, Bae JS, Kim JS, Lim DJ, et al. Cost-effectiveness analysis of active surveillance compared to early surgery in small papillary thyroid cancer: a systemic review. Cancer Manag Res. 2021; 13:6721–30.

14. Kim K, Kim M, Lim W, Kim BH, Park SK. The concept of economic evaluation and its application in thyroid cancer research. Endocrinol Metab (Seoul). 2021; 36:725–36.

15. Uppal N, Cunningham Nee Lubitz C, James B. The cost and financial burden of thyroid cancer on patients in the US: a review and directions for future research. JAMA Otolaryngol Head Neck Surg. 2022; 148:568–75.

16. Cham S, Zanocco K, Sturgeon C, Yeh MW, Harari A. Riskbased ultrasound screening for thyroid cancer in obese patients is cost-effective. Thyroid. 2014; 24:975–86.

17. Oh CM, Kong HJ, Kim E, Kim H, Jung KW, Park S, et al. National Epidemiologic Survey of Thyroid cancer (NEST) in Korea. Epidemiol Health. 2018; 40:e2018052.

18. Oh EY, Jang HW, Lee JI, Kim HK, Kim SW, Chung JH. Prevalence of thyroid nodules and cancer detected by ultrasonography in healthy Korean adults: clinical features and the risk for malignancy. Int J Thyroidol. 2010; 3:142–8.

19. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021 Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2021; 22:2094–123.

20. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:1856–83.

21. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26:1–133.

22. Gupta N, Verma R, Dhiman RK, Rajsekhar K, Prinja S. Cost-effectiveness analysis and decision modelling: a tutorial for clinicians. J Clin Exp Hepatol. 2020; 10:177–84.

23. Baek HS, Ha J, Kim K, Bae J, Kim JS, Kim S, et al. Cost-effectiveness of active surveillance compared to early surgery of small papillary thyroid cancer: a retrospective study on a Korean population. J Korean Med Sci. 2023; 38:e264.

24. National Cancer Information Center. Cancer statistics according to age [Internet]. Goyang: National Cancer Information Center;2024. [cited 2024 Feb 4]. Available from: https://www.cancer.go.kr/lay1/S1T639C642/contents.do.

25. Statistics Korea. Life expectancy [Internet]. Daejeon: Statistics Korea;2023. [cited 2024 Feb 4]. Available from: https://www.index.go.kr/unify/idx-info.do?idxCd=8016.

26. Zhang HS, Lee EK, Jung YS, Nam BH, Jung KW, Kong HJ, et al. Total thyroidectomy’s association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: analysis of Korean nationwide data. Surgery. 2019; 165:629–36.

27. Korean Statistical Information Service. Life table [Internet]. Daejeon: Statistics Korea;2023. [cited 2024 Feb 4]. Available from: https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B42&conn_path=I2.

28. Health Insurance Review & Assessment Service. 2021 Economic evaluation guidelines in medicine and drugs [Internet]. Wonju: HIRA;2021. [cited 2024 Feb 4]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=8661.

29. Kim K, Choi JY, Kim SJ, Lee EK, Lee YK, Ryu JS, et al. Active surveillance versus immediate surgery for low-risk papillary thyroid microcarcinoma patients in South Korea: a cost-minimization analysis from the MAeSTro Study. Thyroid. 2022; 32:648–56.

30. Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016; 94:925–30.

31. Kim YH, Shin SJ, Kim YJ, Lee HJ, Lee SK, Park SY, et al. NECA’s methodological guide for economic evaluation of medical intervention. Seoul: National Evidence-based Healthcare Collaborating Agency;2021.

32. Health Insurance Review & Assessment Service. 2018-2022 ICER [Internet]. Wonju: 2023. [cited 2024 Feb 4]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=10648.

33. Health Insurance Review & Assessment Service. ICER first published 2022 [Internet]. Wonju: 2022. [cited 2024 Feb 4]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020041000100&brdScnBltNo=4&brdBltNo=10774&pageIndex=1&pageIndex2=1#none.

34. Health Insurance Review & Assessment Service. Medical fee schedule of health service in Korea under national health insurance coverage [Internet]. Wonju: 2021; [cited 2024 Feb 4]. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020002000100&brdScnBltNo=4&brdBltNo=9105.

35. Kwon H, Jeon MJ, Kim WG, Park S, Kim M, Song DE, et al. A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol. 2017; 176:371–8.

36. Jeon YW, Gwak HG, Lim ST, Schneider J, Suh YJ. Longterm prognosis of unilateral and multifocal papillary thyroid microcarcinoma after unilateral lobectomy versus total thyroidectomy. Ann Surg Oncol. 2019; 26:2952–8.

37. Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery. 2017; 161:485–92.

38. Oh HS, Ha J, Kim HI, Kim TH, Kim WG, Lim DJ, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid. 2018; 28:1587–94.

39. Kim SH, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, et al. Differences in the recurrence and survival of patients with symptomatic and asymptomatic papillary thyroid carcinoma: an observational study of 11,265 person-years of follow-up. Thyroid. 2016; 26:1472–9.

40. Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, et al. The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk. J Clin Endocrinol Metab. 2015; 100:4434–40.

41. Houten R, Fleeman N, Kotas E, Boland A, Lambe T, Duarte R. A systematic review of health state utility values for thyroid cancer. Qual Life Res. 2021; 30:675–702.

42. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372:621–30.

43. Kim SY, Kim SM, Chang H, Kim BW, Lee YS, Chang HS, et al. Safety of tyrosine kinase inhibitors in patients with differentiated thyroid cancer: real-world use of lenvatinib and sorafenib in Korea. Front Endocrinol (Lausanne). 2019; 10:384.

44. Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974-2018. Pharmacoeconomics. 2020; 38:1135–45.

45. Jones E, Epstein D, Garcia-Mochon L. A procedure for deriving formulas to convert transition rates to probabilities for multistate Markov models. Med Decis Making. 2017; 37:779–89.

46. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022; 25:10–31.

47. Hammer MM, Kong CY. Cost-effectiveness of follow-up ultrasound for incidental thyroid nodules on CT. AJR Am J Roentgenol. 2022; 218:615–22.

48. Ernst R. Indirect costs and cost-effectiveness analysis. Value Health. 2006; 9:253–61.